MARKET

MXCT

MXCT

Maxcyte
NASDAQ
1.210
+0.030
+2.54%
Closed 19:34 08/10 EDT
OPEN
1.170
PREV CLOSE
1.180
HIGH
1.225
LOW
1.160
VOLUME
925.56K
TURNOVER
0
52 WEEK HIGH
1.865
52 WEEK LOW
0.6434
MARKET CAP
129.62M
P/E (TTM)
-3.2979
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MXCT last week (0803-0807)?
Weekly Report · 1d ago
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
NASDAQ · 5d ago
Weekly Report: what happened at MXCT last week (0727-0731)?
Weekly Report · 08/03 09:15
Weekly Report: what happened at MXCT last week (0720-0724)?
Weekly Report · 07/27 09:16
Analysts Conflicted on These Healthcare Names: 10x Genomics (TXG), Celldex (CLDX) and MaxCyte (MXCT)
TipRanks · 07/22 12:30
MaxCyte Signs Multi-Platform Technology License Partnership With Genentech
NASDAQ · 07/22 08:01
MaxCyte enters technology license partnership with Genentech
TipRanks · 07/21 12:45
MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs
Benzinga · 07/21 12:06
More
About MXCT
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Webull offers MaxCyte Inc stock information, including NASDAQ: MXCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MXCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MXCT stock methods without spending real money on the virtual paper trading platform.